Sandra E Talbird

Summary

Affiliation: RTI International
Country: USA

Publications

  1. ncbi A steady-state, population-based model to estimate the direct and indirect effects of pneumococcal vaccines
    Sandra E Talbird
    RTI Health Solutions, PO Box 12194, 3040 Cornwallis Road, Research Triangle Park, NC 27709, USA
    Vaccine 28:G3-13. 2010
  2. ncbi Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States
    Sandra E Talbird
    RTI Health Solutions, Research Triangle Park, NC 27709 2194, USA
    Am J Health Syst Pharm 66:469-80. 2009
  3. ncbi Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S
    Sandra E Talbird
    Research Triangle Institute RTI, Health Solutions, Research Triangle Park, NC 27709, USA
    Am J Prev Med 37:381-8. 2009
  4. ncbi Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae-associated disease following vaccination with PCV-7: a multicountry analysis
    Sandra E Talbird
    RTI Health Solutions, PO Box 12194, 3040 Cornwallis Road, Research Triangle Park, NC 27709, USA
    Vaccine 28:G14-22. 2010
  5. ncbi Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries
    Sandra E Talbird
    RTI Health Solutions, PO Box 12194, 3040 Cornwallis Road, Research Triangle Park, NC 27709, USA
    Vaccine 28:G23-9. 2010
  6. ncbi Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection
    Josephine Mauskopf
    RTI Health Solutions, Research Triangle Park, North Carolina, USA
    AIDS 26:355-64. 2012
  7. ncbi Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States
    Anita J Brogan
    RTI Health Solutions, Research Triangle Park, NC 27709, USA
    Value Health 14:657-64. 2011

Detail Information

Publications7

  1. ncbi A steady-state, population-based model to estimate the direct and indirect effects of pneumococcal vaccines
    Sandra E Talbird
    RTI Health Solutions, PO Box 12194, 3040 Cornwallis Road, Research Triangle Park, NC 27709, USA
    Vaccine 28:G3-13. 2010
    ..8% reduction in invasive disease; this result was similar to other models and a recent observational study in Canada, providing preliminary validation of the model...
  2. ncbi Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States
    Sandra E Talbird
    RTI Health Solutions, Research Triangle Park, NC 27709 2194, USA
    Am J Health Syst Pharm 66:469-80. 2009
    ..The cost-effectiveness of treating influenzalike illness (ILI) with oseltamivir in the United States was assessed...
  3. ncbi Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S
    Sandra E Talbird
    Research Triangle Institute RTI, Health Solutions, Research Triangle Park, NC 27709, USA
    Am J Prev Med 37:381-8. 2009
    ..Given limited healthcare budgets, it is important to understand the costs and cost effectiveness of PEP in children...
  4. ncbi Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae-associated disease following vaccination with PCV-7: a multicountry analysis
    Sandra E Talbird
    RTI Health Solutions, PO Box 12194, 3040 Cornwallis Road, Research Triangle Park, NC 27709, USA
    Vaccine 28:G14-22. 2010
    ..Sp- and NTHi-associated diseases continue to result in substantial direct medical and caregiver costs despite current PCV-7 vaccination programs...
  5. ncbi Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries
    Sandra E Talbird
    RTI Health Solutions, PO Box 12194, 3040 Cornwallis Road, Research Triangle Park, NC 27709, USA
    Vaccine 28:G23-9. 2010
    ..Scenario analysis showed the incremental cost savings for PHiD-CV compared with PCV-7 in the steady-state year were sensitive to assumptions regarding duration of vaccine efficacy...
  6. ncbi Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection
    Josephine Mauskopf
    RTI Health Solutions, Research Triangle Park, North Carolina, USA
    AIDS 26:355-64. 2012
    ....
  7. ncbi Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States
    Anita J Brogan
    RTI Health Solutions, Research Triangle Park, NC 27709, USA
    Value Health 14:657-64. 2011
    ..To estimate the cost-effectiveness of once-daily tenofovir/emtricitabine compared with twice-daily zidovudine/lamivudine and once-daily abacavir/lamivudine in treatment-naïve adults with HIV-1 infection in the United States...